Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | IDH1 | O75874 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920070 | 0.86 | GRM1 (0.48) | MEN1KMT2AGRM1GRM4IDH1 | |
| SCHEMBL3461797 | 0.85 | GRM1 (0.54) | MEN1KMT2AMAPTGRM1GRM4 | |
| SCHEMBL9920068 | 0.81 | GRM1 (0.44) | MEN1KMT2AGRM1GRM4CA12 | |
| SCHEMBL5960012 | 0.79 | GRM1 (0.45) | MEN1KMT2AGRM1GRM4CA12 | |
| SCHEMBL9920067 | 0.78 | GRM1 (0.48) | MEN1KMT2AGRM1GRM4ESR1 | |
| SCHEMBL9919128 | 0.77 | GRM1 (0.47) | RECQLMEN1KMT2AMAPTGRM1 | |
| SCHEMBL11728418 | 0.77 | PTPN1 (0.49) | MAPTGRM1GRM4 | |
| SCHEMBL9920069 | 0.75 | GRM1 (0.41) | MEN1KMT2AMAPTGRM1GRM4 | |
| SCHEMBL12706573 | 0.75 | GRM1 (0.55) | GRM1GRM4ESR1ESR2 | |
| SCHEMBL1972070 | 0.75 | GRM4 (0.69) | GRM1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314593-B1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2314593-A1 | Platelet ADP receptor inhibitors | Portola Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1734041-A2 | Platelet ADP receptor inhibitors | Portola Pharmaceuticals, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1412364-B1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060194795-A1 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-7056926-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050228029-A1 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, particularly those diseases related to thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-6906063-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1412364-A1 | PLATELET ADP RECEPTOR INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011872-A1 | PLATELET ADP RECEPTOR INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020077486-A1 | For therapy and prophylaxis of thrombosis in a mammal | ALEXION PHARMACEUTICALS, INC. | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | RECQL 1798/4885MEN1 4498/4885KMT2A 3009/4885 |
| US-20050228029-A1 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, particularly those diseases related to thrombosis | PIGS, ABCC9, TBXA2R | RECQL 2644/4885MEN1 4275/4885KMT2A 2793/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | RECQL 1802/4885MEN1 4499/4885KMT2A 3023/4885 |
| US-20020077486-A1 | For therapy and prophylaxis of thrombosis in a mammal | PIGS, TBXA2R, GP6 | RECQL 1943/4885MEN1 4149/4885KMT2A 2781/4885 |
| US-20060194795-A1 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PIGS, ABCC9, TBXA2R | RECQL 2878/4885MEN1 4297/4885KMT2A 2772/4885 |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PTAFR, ADGRF1, P2RY6 | RECQL 987/4885MEN1 4529/4885KMT2A 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.